Dermira Inc (DERM) Director David E. Cohen Sells 600 Shares

Dermira Inc (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $28.03, for a total value of $16,818.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Dermira Inc (DERM) traded up $0.21 during midday trading on Friday, reaching $26.70. The company’s stock had a trading volume of 737,900 shares, compared to its average volume of 767,237. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a 52-week low of $21.35 and a 52-week high of $38.75. The firm has a market cap of $1,110.00, a price-to-earnings ratio of -4.29 and a beta of 0.80.

A number of research firms recently weighed in on DERM. BidaskClub lowered Dermira from a “buy” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald reissued a “buy” rating and set a $45.00 target price on shares of Dermira in a report on Tuesday, September 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Dermira in a report on Sunday, September 17th. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, Guggenheim reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Dermira in a report on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $41.00.

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA grew its holdings in Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 3,975 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 2,309 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,203 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Dermira by 40.9% during the 2nd quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 2,803 shares in the last quarter. Finally, Ardsley Advisory Partners acquired a new stake in shares of Dermira during the 2nd quarter worth $291,000. 99.47% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Dermira Inc (DERM) Director David E. Cohen Sells 600 Shares” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/01/12/dermira-inc-derm-director-david-e-cohen-sells-600-shares.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply